11 results about "Herpes simplex virus" patented technology

Compositions and methods discussed herein provide for treatment or prevention of a disease or disorder, or its symptoms, using a modified herpes simplex virus (mHSV) vector comprising at least two transgenes, wherein at least a first transgene encoding a gene-editing system, gene-deletion system, or bridge-editing system is expressed to knock out or delete an endogenous target gene and at least a second transgene encoding a corrected copy of the endogenous targeted gene, wherein the gene product of the second transgene replaces the gene product of the endogenous target gene.

(A first) anti-HSV antibody or an antigen-binding fragment thereof that binds to glycoprotein B (gB) of HSV-1 and / or HSV-2, wherein the antibody comprises complementarity-determining regions V each containing the sequences defined in the claims H CDR1, V H CDR3, V L CDR1, V L CDR2, and V L CDR3, and wherein the antibody or its antigen-binding fragment has a maximum dissociation rate k -4 s -1 of at most 5.0 x 10 -4 s -1 preferably at most 1.0 x 10 -5 s -1 most preferably at most 2.9 x 10 -5 s -1 is described. Further, (A) the (first) anti-HSV antibody or its antigen-binding fragment, and (B) a second anti-HSV antibody or its antigen-binding fragment that recognizes / binds to glycoprotein B (gB) of HSV-1 and / or HSV-2, wherein the antibody comprises complementarity-determining regions V each containing the sequences defined in the claims dis CDR1, V H CDR1, V H CDR2, V H CDR3, V L CDR1, V L CDR2, and V LA combination of a second anti-HSV antibody or its antigen-binding fragment is described, comprising CDR3, wherein the second antibody has a dissociation constant Kd of up to 40 nM, preferably up to 30 nM, more preferably up to 20 nM, even more preferably up to 15 nM, up to 13 nM, and up to 10 nM. Furthermore, a pharmaceutical composition is described comprising an effective amount of the anti-HSV antibody or its antigen-binding fragment, or the combination of the antibodies, and at least one pharmaceutically acceptable excipient. Furthermore, the anti-HSV antibody or its antigen-binding fragment or the combination of the antibodies is described for use in a method for the prophylactic or therapeutic treatment of a disorder or disease as defined in the claims. Furthermore, (A) V, which is the complementarity-determining region of the first antibody described above. H CDR1, V H CDR2, V H CDR3, V L CDR1, V L CDR2, and V L (B) The first binding domain containing CDR3 and (B) the complementarity determining region of the second antibody described above. H CDR1, V H CDR2, V H CDR3, V L CDR1, V L CDR2, and V L A bispecific antibody that binds to glycoprotein B(gB) of HSV-1 and / or HSV-2, comprising a second binding domain containing CDR3, with a maximum capacity of 5.0 x 10⁻¹⁴. -4 s -1 Preferably a maximum of 1.0 x 10 -4 s -1 , up to 5.0x10 -5 s -1 Most preferably a maximum of 2.9 x 10 -5 s -1 A bispecific antibody having a low dissociation rate of kdis is described. Finally, a triplicate antibody is described that includes a third binding domain in addition to the first and second binding domains described for the bispecific antibody.

Disclosed herein is a method for predicting prognosis of a subject being with a cancer, such as a malignant glioma, being treated with an oncolytic herpes simplex virus (oHSV) that involves assaying a sample from the subject for Acyl-CoA-binding protein (ACBP) levels, wherein an elevated level of ACBP compared to a control is an indication of a poor prognosis. Also disclosed herein is a method for treating a cancer, such as a malignant glioma, in a subject that involves administering to the subject an effective amount of an oncolytic herpes simplex virus (oHSV) in combination with a glioma Bmi1 inhibitor or a fatty acid oxidation (FAO) inhibitor optionally followed by one or more immune checkpoint inhibitors.

This invention discloses a recombinant herpes simplex virus vector expressing a HER2-deficient tyrosine kinase domain and its anti-tumor application, belonging to the fields of genetic engineering and tumor therapy. The vector is constructed via CRISPR / Cas9-mediated homologous recombination. After co-transfecting 293T cells with the pX459-γ34.5-KO vector and a homologous recombination target fragment expressing a HER2-deficient tyrosine kinase domain sequence, wild-type herpes simplex virus type 1 infection-mediated recombination is used to achieve targeted replacement of the viral γ34.5 site with the target sequence. This vector can efficiently infect HER2-negative / low-expressing tumor cells and enhance the killing effect of HER2-targeting antibody-drug conjugates (T-DM1 or T-DXd). In vitro and in vivo experiments have confirmed that it has significant anti-tumor activity, either alone or in combination with HER2-targeting antibody-drug conjugates, with no significant damage to vital organs and good safety, providing a new strategy for the treatment of related tumors.

This invention provides a method for characterizing recombinant viral particle preparations using analytical ultracentrifugation. The recombinant viral particles include recombinant adeno-associated viral particles, recombinant adenovirus particles, recombinant lentivirus particles, and recombinant herpes simplex virus particles. Different variants of recombinant viral particles, including empty capsids and recombinant viral particles with different genomes (e.g., truncated genomes, aggregates, recombinants), can be identified and quantified. This method can be used to characterize recombinant viral particle preparations regardless of the genomic sequence of the recombinant virus or the serotype of the recombinant viral capsid.

Provided are primers and probes for single-tube multiplex fluorescent PCR detection of Treponema pallidum, herpes simplex virus 1 and herpes simplex virus 2, a fluorescent PCR kit, and the use thereof. The primers comprise specific sequences for Treponema pallidum, herpes simplex virus 1 and herpes simplex virus 2, respectively, which sequences have no cross-reaction. The specific sequences of the primers and probes are as shown in SEQ ID NO:1 to SEQ ID NO:9. A plurality of sexually transmitted pathogens such as Treponema pallidum, herpes simplex virus 1, and herpes simplex virus 2 can be detected simultaneously.

The application discloses a private part care spray capable of balancing private part microecology, removing peculiar smell, killing bacteria and resisting viruses, and belongs to the technical field of private part care and disinfection materials. The private part care spray is prepared by compounding 3.8-6.5 parts of a modified edible bactericide, 3.2-5.5 parts of food-grade lactic acid, 2.2-3.0 parts of modified food-grade gentian root extract and the rest food-grade deionized water. The activity and stability of raw materials are improved through the processes of β-cyclodextrin inclusion modification of the bactericide and compounding of the modified product with the modified food-grade gentian root extract. The product has a killing rate of 99.9% on Neisseria gonorrhoeae, Gardnerella vaginalis, Bacteroides, Streptococcus pyogenes, Candida albicans, Staphylococcus epidermidis, Escherichia coli and Pseudomonas aeruginosa, an inactivation rate of 99.99% on herpes simplex virus SHV-2 and HPV16 virus, an ammonia removal rate of 95%, a peculiar smell inhibition duration of 48 h and a mucous membrane irritation level of 0, and the preparation process is simple and suitable for industrial production.

Described herein are compositions and methods for providing a viable therapeutic approach to latent herpes simplex virus type 2 (HSV-2) infection by reducing or eliminating latent HSV-2 from HSV-2-infected cells, or by reducing or eliminating the reactivation of latent HSV-2 in HSV-2-infected cells. The compositions comprise a plurality of viral vectors, each comprising a sequence encoding an HSV-2-specific meganuclease. The methods comprise the step of delivering a plurality of viral vectors to HSV-2-infected cells, each of which comprises a sequence encoding an HSV-2-specific meganuclease.

The present application relates to a kind of orthogonal type DNA self-replicating vector and its use in mammal to express gene of interest.The vector includes the expression cassette of the replication essential gene of type I herpes simplex virus and replication initiation sequence, wherein the replication essential gene of type I herpes simplex virus is UL9, UL29, UL30, UL42, UL5, UL8 and UL52, and the replication initiation sequence is OriS and / or OriL.